IDH1 mutations in MDS are crucial for guiding therapy decisions, offering one of the few targetable mutations in this disease ...

In standard radiotherapy, the radiation interacts with water in tissue, creating electrons or reactive oxygen species that ...

Dr. Colette Shen discusses unmet needs in recurrent head and neck cancer, highlighting a novel treatment study aimed at ...

Close monitoring via weekly complete blood counts (CBCs) for the first 2 months is essential to mitigate risks, according to Zeidan. Supportive care such as platelet transfusions or growth factors may ...

The hydrogel spacer minimizes radiation exposure to the rectum, decreasing bowel, urinary, and sexual complications. Recent analysis reveals that rectal spacers significantly lower recurrence rates in ...

BCMA-targeting CAR T-cell therapy shows similar efficacy and safety for REMPs and non-REMPs, despite access disparities. REMPs experience reduced access to CAR T therapy, with significant drops in ...

Results from a phase 1-2 clinical study (NCT05296122) 1 showed that safety and feasibility measures among patients with primary and recurrent glioblastoma and grade 4 astrocytoma could be met using ...

The Paloma-3 study provided important insights into patient-reported outcomes with the subcutaneous formulation of amivantamab. Historically, cancer treatment focused primarily on ...

An expert discusses how maintenance lurbinectedin benefits patients across subgroups, including those with liver metastases, and may be considered for patients with brain metastases after radiation ...

An expert discusses how maintenance lurbinectedin plus atezolizumab should be followed by standard second-line tarlatamab therapy at progression, as the maintenance approach doesn't change subsequent ...